In the phase 1/2 trial, alpelisib (a PI3K inhibitor) plus nab-paclitaxel was well tolerated and showed encouraging efficacy, especially in patients with metastatic PIK3CA -mutated HER2 breast cancer, despite that TNBC has lower efficacy than HR+/HER2 patients
Participants also reported increased cognitive or dietary restraint (which relates to how much people intentionally limit their eating), but the researchers say more research is needed to understand this link
Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging
Critical Warning : This guide is based on methods used in scientific research
Results should be considered with standard cardiovascular markers, medical history, and clinical evaluation
Check out our blog section to find out more about BPC-157 and get answers to all your questions